Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PRA052 in Healthy Volunteers
NCT05603182Phase 1Completed
- Sponsor
- Prometheus Biosciences
- Start
- Nov 2022
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-8690 in ulcerative colitis (UC) (4 arms), sponsored by Prometheus Biosciences. Primary endpoint: Treatment emergent adverse events up to 20 weeks. Started Nov 2022; status: completed.
02
Drugs
MK-8690
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05603182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603182.